Representative imageCompanies without existing US manufacturing plants could face the full impact, triggering declines across major drugmakers in South Korea, Japan, and Hong Kong.In South Korea, Samsung Biologics fell 1.6%, while SK Biopharmaceuticals slid 2.6%. Celltrion, which recently acquired ImClone Systems from Eli Lilly in the United States for $330 million, rose 1.3% after recouping earlier losses.In Japan, Sumitomo Pharma tumbled 4.3%, Otsuka Holdings dropped 3.5%, and Daiichi Sankyo lost 1.6%. Ta ...

Core Insights - RH Inc. shares dropped 3.39% to $204.14 in after-hours trading following President Trump's tariff announcement targeting home furnishings [1] - The U.S. will impose a 30% tariff on upholstered furniture and a 50% tariff on bathroom vanities, attributed to a "massive influx" of foreign products [2] - All tariff measures will take effect on October 1, including a 25% tariff on heavy-duty trucks and a 50% tariff on kitchen cabinets [3] Stock Performance - RH closed at $211.30 on Thursday, down 0.62% for the regular session, and has fallen 46.31% year-to-date with a 52-week range of $123.03-$457.26 [3] - The company's market capitalization is $3.96 billion with a price to earnings ratio of 39.30 [3] - RH reached a peak of $454.52 on January 2, showing a 53.51% decline from that peak [4] Market Sentiment - Benzinga's Edge Stock Rankings indicate that RH is experiencing medium-term upward movement despite recent declines [4]

Group 1 - Asian share markets experienced a significant selloff, particularly in drugmakers and furniture makers, following the announcement of new tariffs by U.S. President Donald Trump [1][5] - The new tariffs include a 100% duty on branded drugs and a 25% tariff on heavy-duty trucks, effective from October 1, which could impact global drugmakers and manufacturers [1][4] - Companies like Paccar-owned Peterbilt and Kenworth, as well as Daimler Truck-owned Freightliner, may benefit from the tariffs on heavy-duty trucks [4] Group 2 - The Trump administration's trade deals with Japan, the EU, and the UK include provisions that cap tariffs for specific products, which may limit the impact of the new tariffs on certain sectors [3] - Global drugmakers are proactively increasing their U.S. manufacturing capacity and domestic inventory in response to the new tariffs [3] - The market is currently pricing in approximately 39 basis points of easing by December, reflecting a shift in expectations regarding U.S. interest rate cuts due to tariff-related inflation concerns [6]

Emerging-market assets drop as the fresh round of US tariffs including a 100% duty on branded or patented pharmaceuticals hurt sentiment https://t.co/JRdoOw9UR0 ...

Market Overview - Indian stocks experienced a decline, with the Sensex and Nifty extending losses for the sixth consecutive session, primarily driven by concerns over new tariffs imposed by U.S. President Donald Trump on pharmaceutical products [15][16] - The S&P BSE Sensex fell by 235.99 points, or 0.29%, opening at 80,923.69, while the NSE Nifty 50 decreased by 80.35 points, or 0.32%, opening at 24,810.50 [15][16] Pharmaceutical Sector Impact - The Nifty Pharma index dropped 2.3%, with all constituents trading lower; Sun Pharma fell 5% to a 52-week low, while Biocon and other major pharmaceutical companies also experienced declines [15][16] - The U.S. accounts for over a third of India's pharmaceutical exports, which mainly consist of low-cost generic drugs; shipments to the U.S. increased by 20% to approximately $10.5 billion in FY25 [3][15] Tariff Announcements - President Trump announced a 100% tariff on branded and patented drugs and a 25% tariff on heavy-duty trucks, effective October 1, which has negatively affected market sentiment [4][16] - Analysts suggest that while India, as an exporter of generic drugs, may not be immediately impacted, there are concerns that future tariffs could target generic drugs, potentially affecting pharmaceutical stocks sentiment [7][16] Broader Market Trends - The midcap and smallcap indices also fell, by 0.8% and 1.2% respectively, reflecting a broader market decline [4][16] - Asian stocks declined overall, with significant losses in pharmaceutical shares following the tariff announcements, indicating a regional impact on the sector [10][11] Institutional Investment Activity - Foreign Institutional Investors (FIIs) sold equities worth over ₹4,995 crore on September 25, while Domestic Institutional Investors (DIIs) were net buyers of ₹5,103 crore [12][16] Technical Analysis - Technical analysts indicate that the market is near the 20-day Simple Moving Average (SMA), suggesting a potential pullback; however, if upswings are limited, the downside objective could extend to 24,680 [9][16]

Core Viewpoint - Shares of Asian drugmakers experienced a decline following U.S. President Donald Trump's announcement of potential 100% tariffs on imports of branded pharmaceuticals starting October 1, contingent upon the establishment of U.S. manufacturing plants by their producers [1] Group 1 - The announcement by President Trump poses a significant threat to Asian drugmakers, as it could lead to increased costs and reduced competitiveness in the U.S. market [1] - The tariffs are aimed at encouraging pharmaceutical companies to invest in domestic manufacturing, which could reshape the industry landscape [1] - The potential implementation of these tariffs may lead to a broader impact on global supply chains and pricing strategies within the pharmaceutical sector [1]

By Gregor Stuart Hunter and Andrew Silver SINGAPORE/SHANGHAI (Reuters) -Shares of U.S. and European pharmaceutical firms were little changed on Friday, while Asian drugmakers declined, after President Donald Trump announced 100% tariffs on branded drugs imported by firms that are not building plants in the U.S. Analysts said the move was widely expected and unlikely to materially hit the industry, given that most drugmakers have pledged billions of dollars in U.S. manufacturing investments. The condit ...

Summary of Key Points from the Conference Call Industry Overview - The conference call discusses the global economic outlook, focusing on the impact of tariffs and inflation on growth trajectories across various economies, particularly the United States and its trading partners [1][2][3][4][5]. Core Insights and Arguments 1. **Global Growth Trajectory**: - Global growth is projected to have run at 2.6% during the first half of the year, slightly down from 2.8% last year, indicating resilience despite tariff-related uncertainties [1][9]. - A slowdown to below 2% is anticipated in the second half of the year, with a rebound to 2.5% expected next year [1][24]. 2. **Impact of Tariffs**: - The expectation of rising tariffs has led US households and firms to frontload purchases, resulting in US imports running above 2024 levels [2][17]. - Tariff collections reached $30 billion in August, annualized to $360 billion, significantly higher than $75 billion last year [21]. 3. **Inflation Dynamics**: - Global headline inflation remains around 2%, while core inflation has plateaued at 2.5%, reflecting a gradual decline in services inflation [4][36]. - Consumers have absorbed only 30-40% of tariff costs, with firms delaying price increases due to inventory accumulation [3][21]. 4. **Monetary Policy Trends**: - Global monetary policy is on a gradually easing trajectory, with major central banks either cutting rates or holding steady [5][51]. - The Federal Reserve has cut rates and signaled further cuts, while the European Central Bank is expected to pause before potentially trimming rates again [54][55]. 5. **US Consumption Outlook**: - A softening of US consumption and imports is expected in the coming quarters, influenced by the frontloading of purchases and rising prices due to tariffs [22][24]. - The recent weakening of the US labor market aligns with this outlook, suggesting reduced real spending as tariffs drive prices higher [24]. Additional Important Insights 1. **Global Economic Resilience**: - The global economy has shown remarkable flexibility, adapting to various shocks over the past five years, maintaining solid growth despite challenges [20]. - The resilience is attributed to factors such as frontloading of imports and adjustments in consumer behavior [17][20]. 2. **Sector-Specific Impacts**: - The auto sector has experienced mild compression in import prices, while consumer goods and capital goods show little impact from tariffs [34]. - China has seen a significant decline in its share of US imports, dropping to 8% in Q2 2025 from over 20% in early 2018 due to tariffs exceeding 50% on some goods [18]. 3. **Future Projections**: - The forecast indicates a gradual return to neutral monetary policy across various countries, with no significant moves into accommodative territory expected [61]. - The divergence in inflation impacts between the US and the rest of the world is highlighted, with US tariffs acting as a stagflationary shock while reducing demand for exports from other countries [37][38]. This summary encapsulates the key points discussed in the conference call, providing a comprehensive overview of the current economic landscape and future expectations.

Group 1 - President Trump announced new tariffs set to begin on October 1, including 100% duties on imported branded or patented pharmaceuticals, 25% tariffs on heavy-duty trucks, and 50% tariffs on kitchen cabinets [1] - The rationale behind these tariffs is to combat the "flooding" of these products into the U.S. from other countries, which is deemed an unfair practice that threatens national security and domestic manufacturing [2] - The decision to raise tariffs appears unaffected by rising inflation rates, with the consumer price index increasing by 3.1% in August, and significant price hikes in the "food at home" category [3]

Group 1 - Wall Street indexes experienced gains on Friday but still recorded a loss for the week, with consumer spending supporting longer-dated Treasury yields and gold prices rising due to steady inflation readings [1][3] - Consumer spending increased slightly more than expected in August, while the inflation rate rose to 2.7% from 2.6% in July, aligning with economists' expectations [1] - Analysts noted that some companies managed to mitigate price pressures by stockpiling in anticipation of tariffs, but upcoming corporate earnings releases will be a significant test for many firms [2] Group 2 - The Dow Jones Industrial Average rose by 0.65%, the S&P 500 increased by 0.59%, and the Nasdaq Composite was up by 0.44% [3] - Individual stocks reacted to new White House tariffs, with Paccar gaining 5% and Eli Lilly rising 1.5% [3] - Richmond Fed Bank President expressed low confidence in inflation forecasts due to ongoing tariff impacts on the economy [3] Group 3 - The personal consumption expenditures index is a key component of the Federal Reserve's inflation outlook, with U.S. Treasury yields showing minimal movement after data release [5] - The yield on benchmark U.S. 10-year notes rose by 0.7 basis points to 4.181%, while the 30-year bond yield increased by 0.5 basis points to 4.7576% [5] - Gold prices, typically benefiting from lower interest rates, held onto recent gains, with spot prices quoted at $3,766.25 an ounce, up by 0.46% [6] Group 4 - Investors currently estimate an 89.8% probability of a rate cut in October and a 67% chance of another cut in December, according to the CME FedWatch Tool [7]